London
· Delayed Price · Currency is GBP · Price in GBXTissue Regenix Group Statistics
Total Valuation
Tissue Regenix Group has a market cap or net worth of GBP 42.38 million. The enterprise value is 47.38 million.
| Market Cap | 42.38M |
| Enterprise Value | 47.38M |
Important Dates
The last earnings date was Tuesday, September 10, 2024.
| Earnings Date | Sep 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Tissue Regenix Group has 71.23 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Shares Outstanding | 71.23M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 24.60% |
| Owned by Institutions (%) | 46.60% |
| Float | 45.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.66 |
| PB Ratio | 1.76 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 43.39, with an EV/FCF ratio of -604.85.
| EV / Earnings | -54.39 |
| EV / Sales | 1.88 |
| EV / EBITDA | 43.39 |
| EV / EBIT | 164.96 |
| EV / FCF | -604.85 |
Financial Position
The company has a current ratio of 3.74, with a Debt / Equity ratio of 35.69.
| Current Ratio | 3.74 |
| Quick Ratio | 1.47 |
| Debt / Equity | 35.69 |
| Debt / EBITDA | 7.59 |
| Debt / FCF | -105.78 |
| Interest Coverage | 0.49 |
Financial Efficiency
Return on equity (ROE) is -3.31% and return on invested capital (ROIC) is 0.57%.
| Return on Equity (ROE) | -3.31% |
| Return on Assets (ROA) | 0.50% |
| Return on Capital (ROIC) | 0.57% |
| Revenue Per Employee | 306,829 |
| Profits Per Employee | -10,624 |
| Employee Count | 82 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 1.33 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +10.19% |
| 50-Day Moving Average | 65.32 |
| 200-Day Moving Average | 62.25 |
| Relative Strength Index (RSI) | 25.50 |
| Average Volume (20 Days) | 29,958 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Tissue Regenix Group had revenue of GBP 25.16 million and -871,188 in losses. Loss per share was -0.01.
| Revenue | 25.16M |
| Gross Profit | 12.45M |
| Operating Income | 287,231 |
| Pretax Income | -485,840 |
| Net Income | -871,188 |
| EBITDA | 981,966 |
| EBIT | 287,231 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 2.74 million in cash and 8.29 million in debt, giving a net cash position of -5.55 million or -0.08 per share.
| Cash & Cash Equivalents | 2.74M |
| Total Debt | 8.29M |
| Net Cash | -5.55M |
| Net Cash Per Share | -0.08 |
| Equity (Book Value) | 23.22M |
| Book Value Per Share | 0.34 |
| Working Capital | 12.14M |
Cash Flow
In the last 12 months, operating cash flow was 283,275 and capital expenditures -361,610, giving a free cash flow of -78,335.
| Operating Cash Flow | 283,275 |
| Capital Expenditures | -361,610 |
| Free Cash Flow | -78,335 |
| FCF Per Share | -0.00 |
Margins
Gross margin is 49.48%, with operating and profit margins of 1.14% and -3.46%.
| Gross Margin | 49.48% |
| Operating Margin | 1.14% |
| Pretax Margin | -1.93% |
| Profit Margin | -3.46% |
| EBITDA Margin | 3.90% |
| EBIT Margin | 1.14% |
| FCF Margin | -0.31% |
Dividends & Yields
Tissue Regenix Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.08% |
| Shareholder Yield | -0.08% |
| Earnings Yield | -2.08% |
| FCF Yield | -0.18% |
Stock Splits
The last stock split was on April 28, 2023. It was a reverse split with a ratio of 0.01.
| Last Split Date | Apr 28, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.01 |